Similar articles

• Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.

  Berkowitz SD. Berkowitz SD. Haemostasis. 2000;30 Suppl 3:27-43. doi: 10.1159/000054195. Haemostasis. 2000. PMID: 11182626 Review.
• A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.

  Tcheng JE. Tcheng JE. Am Heart J. 1999 Oct;138(4 Pt 2):261-2. doi: 10.1053/hj.1999.v138.a100464. Am Heart J. 1999. PMID: 10502231 No abstract available.
• [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

  Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B. Auer J, et al. Herz. 2003 Aug;28(5):393-403. doi: 10.1007/s00059-002-2316-4. Herz. 2003. PMID: 12928738 Review. German.
• [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].

  Patti G, Fossati C, Manzoli A, D'Ambrosio A, Abbate A, Montesanti R, Di Sciascio G. Patti G, et al. Clin Ter. 2000 Jul-Aug;151(4):301-6. Clin Ter. 2000. PMID: 11107681 Review. Italian.
• The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.

  Koller CF. Koller CF. Heart Lung. 2001 Sep-Oct;30(5):321-9; quiz 330-1. doi: 10.1067/mhl.2001.118297. Heart Lung. 2001. PMID: 11604974 Review.